

Howard Cuckle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8354148/publications.pdf>

Version: 2024-02-01

166
papers

6,385
citations

61945

43
h-index

76872

74
g-index

172
all docs

172
docs citations

172
times ranked

3588
citing authors

#	ARTICLE	IF	CITATIONS
1	Maternal weight as an additional first trimester spina bifida screening marker. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 3353-3358.	0.7	1
2	Oligohydramnios: how severe is severe?. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 5754-5760.	0.7	3
3	Cost of providing cell-free DNA screening for Down syndrome in Finland using different strategies. <i>Journal of Perinatal Medicine</i> , 2022, 50, 233-243.	0.6	2
4	Pre-eclampsia screening studies “overcoming intervention bias. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, , .	1.1	0
5	Consequences of imprecision in fetal fraction estimation on performance of cell-free DNA screening for Down syndrome. <i>Prenatal Diagnosis</i> , 2022, , .	1.1	7
6	Modified multiple marker aneuploidy screening as a primary screening test for preeclampsia. <i>BMC Pregnancy and Childbirth</i> , 2022, 22, 190.	0.9	6
7	Re: Routine “first trimester” combined “screening for pre-eclampsia: pregnancy-associated plasma <sc>protein A</sc> or placental growth factor?. <i>Ultrasound in Obstetrics and Gynecology</i> , 2022, 59, 404-404.	0.9	1
8	Evaluation of a Maternal Plasma RNA Panel Predicting Spontaneous Preterm Birth and Its Expansion to the Prediction of Preeclampsia. <i>Diagnostics</i> , 2022, 12, 1327.	1.3	3
9	Quality assessment of first trimester screening for preterm pre-eclampsia. <i>Ultrasound in Obstetrics and Gynecology</i> , 2022, 60, 746-750.	0.9	1
10	Screening for early-onset preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 246.	0.7	1
11	Impact of the COVID-19 Pandemic on Excess Perinatal Mortality and Morbidity in Israel. <i>American Journal of Perinatology</i> , 2021, 38, 398-403.	0.6	56
12	Maternal age in the epidemiology of common autosomal trisomies. <i>Prenatal Diagnosis</i> , 2021, 41, 573-583.	1.1	13
13	Review of epidemiological factors (other than maternal age) that determine the prevalence of common autosomal trisomies. <i>Prenatal Diagnosis</i> , 2021, 41, 536-544.	1.1	8
14	The United States™ experience in nuchal translucency: variation by provider characteristics in over 5 million ultrasound measurements. <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, 58, 732-737.	0.9	1
15	The origins of aneuploidy research consortium. <i>Prenatal Diagnosis</i> , 2021, 41, 642-646.	1.1	1
16	Increase rate of ruptured tubal ectopic pregnancy during the COVID-19 pandemic. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 259, 95-99.	0.5	26
17	Early pregnancy prediction of spontaneous preterm birth before 32 completed weeks of pregnancy using plasma RNA: transcriptome discovery and initial validation of an RNA panel of markers. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, 128, 1870-1880.	1.1	12
18	Cell-free DNA screening for fetal aneuploidy using the rolling circle method: a step towards NIPT simplification. <i>Prenatal Diagnosis</i> , 2021, , .	1.1	7

#	ARTICLE	IF	CITATIONS
19	Downâ€™s Syndrome Screening in the First Trimester with Additional Serum Markers: Indian Parameters. Journal of Obstetrics and Gynecology of India, 2020, 70, 12-17.	0.3	2
20	Ultrasound and Biochemical Screening for Fetal Aneuploidy. , 2020, , 161-175.e3.		0
21	Strategies for Prescribing Aspirin to Prevent Preeclampsia: A Cost-Effectiveness Analysis. Obstetrics and Gynecology, 2020, 135, 217-217.	1.2	10
22	Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial. Lancet Oncology, The, 2020, 21, 1165-1172.	5.1	110
23	Late pregnancy screening for preeclampsia with a urinary point-of-care test for misfolded proteins. PLoS ONE, 2020, 15, e0233214.	1.1	15
24	Cost-Effectiveness of First Trimester Screening for Preterm Pre-eclampsia in Lebanon. Journal of Fetal Medicine, 2020, 7, 119-123.	0.1	7
25	Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT. Health Technology Assessment, 2020, 24, 1-24.	1.3	23
26	Rethinking secondâ€™trimester Downâ€™s syndrome screening in the cellâ€™free DNA era. Ultrasound in Obstetrics and Gynecology, 2019, 54, 431-436.	0.9	2
27	Spina bifida screening in the first trimester using ultrasound biparietal diameter measurement adjusted for crownâ€™rump length or abdominal circumference. Prenatal Diagnosis, 2019, 39, 314-318.	1.1	12
28	Downâ€™s syndrome screening at 11â€™14 weeks' gestation using prenatal thickness and nasal bone length. Archives of Gynecology and Obstetrics, 2019, 299, 939-945.	0.8	4
29	Firstâ€™trimester Abdominal Circumference (Versus Crown Rump Length) Improves Precision in Interâ€™and Intraobserver Variability. Journal of Ultrasound in Medicine, 2019, 38, 2161-2167.	0.8	1
30	Local validation and calibration of preâ€™eclampsia screening algorithms. Ultrasound in Obstetrics and Gynecology, 2019, 53, 724-728.	0.9	4
31	Epidemiology and Genetics of Human Aneuploidy. , 2019, , 529-551.		2
32	Bedside risk estimation of morbidly adherent placenta using simple calculator. Archives of Gynecology and Obstetrics, 2018, 297, 631-635.	0.8	3
33	The mid-gestation triple test profile among women diagnosed with vasa previa. Journal of Maternal-Fetal and Neonatal Medicine, 2018, 31, 1402-1406.	0.7	1
34	Enhanced First Trimester Aneuploidy Screening with Placental Growth Factor and Alpha Feto-Protein: Detection of Trisomies 18 and 13. Journal of Obstetrics and Gynaecology Canada, 2018, 40, 1295-1301.	0.3	4
35	Reply. Ultrasound in Obstetrics and Gynecology, 2017, 49, 158-158.	0.9	0
36	<scp>cfDNA</scp> screening performance: accounting for and reducing test failures. Ultrasound in Obstetrics and Gynecology, 2017, 49, 689-692.	0.9	13

#	ARTICLE	IF	CITATIONS
37	Incorporating thyroid markers in Down syndrome screening protocols. <i>Prenatal Diagnosis</i> , 2017, 37, 510-514.	1.1	5
38	Prenatal Screening Strategies in Localities with Limited Resources. <i>Journal of Fetal Medicine</i> , 2017, 4, 165-170.	0.1	1
39	Re: Cut-off value of nuchal translucency as indication for chromosomal microarray analysis. I. Maya, S. Yacobson, S. Kahana, J. Yeshaya, T. Tenne, I. Agmon-Fishman, L. Cohen-Vig, M. Shohat, L. Basel-Vanagaite and R. Sharony. <i>Ultrasound Obstet Gynecol</i> 2017; 50: 332-335. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 50, 293-294.	0.9	1
40	Rational and irrational ratios. <i>Ultrasound in Obstetrics and Gynecology</i> , 2016, 48, 275-278.	0.9	5
41	First- and second-trimester maternal serum markers of pre-eclampsia in twin pregnancy. <i>Ultrasound in Obstetrics and Gynecology</i> , 2016, 47, 560-564.	0.9	18
42	Maternal Urine Screening for Down Syndrome: Past Studies and Future Perspectives. <i>Journal of Fetal Medicine</i> , 2016, 3, 149-150.	0.1	0
43	Strategies for Implementing Cell-Free DNA Testing. <i>Clinics in Laboratory Medicine</i> , 2016, 36, 213-226.	0.7	3
44	Maternal serum PIGF (placental growth factor) in Chinese women in the first trimester undergoing screening for Down syndrome. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2016, 201, 166-170.	0.5	11
45	Development of prenatal screening – A historical overview. <i>Seminars in Perinatology</i> , 2016, 40, 12-22.	1.1	55
46	Nuchal Translucency Quality Review (NTQR) program: first one and half million results. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 45, 199-204.	0.9	22
47	Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. <i>Prenatal Diagnosis</i> , 2015, 35, 725-734.	1.1	243
48	Noninvasive Prenatal Testing and Fetal Sonographic Screening. <i>Journal of Ultrasound in Medicine</i> , 2015, 34, 363-369.	0.8	4
49	Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 1123-1132.	5.1	159
50	First trimester screening for Down syndrome using nuchal translucency, maternal serum pregnancy-associated plasma protein A, free human chorionic gonadotrophin, placental growth factor, and ß-hCG-fetoprotein. <i>Prenatal Diagnosis</i> , 2015, 35, 709-716.	1.1	38
51	Direct and rapid mass spectral fingerprinting of maternal urine for the detection of Down syndrome pregnancy. <i>Clinical Proteomics</i> , 2015, 12, 9.	1.1	17
52	Cell-free DNA screening for fetal aneuploidy as a clinical service. <i>Clinical Biochemistry</i> , 2015, 48, 932-941.	0.8	75
53	Prenatal Screening Using Maternal Markers. <i>Journal of Clinical Medicine</i> , 2014, 3, 504-520.	1.0	13
54	Extrapolation of maternal weight in sequential aneuploidy screening. <i>Prenatal Diagnosis</i> , 2014, 34, 753-758.	1.1	3

#	ARTICLE	IF	CITATIONS
55	Screening for Down syndrome – incidental diagnosis of other aneuploidies. <i>Prenatal Diagnosis</i> , 2014, 34, 1044-1048.	1.1	14
56	Single-Nucleotide Polymorphism–Based Noninvasive Prenatal Screening in a High-Risk and Low-Risk Cohort. <i>Obstetrics and Gynecology</i> , 2014, 124, 210-218.	1.2	254
57	Clinical utility and cost of non-invasive prenatal testing. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2014, 27, 320-321.	0.7	8
58	Theoretical performance of non-invasive prenatal testing for chromosome imbalances using counting of cell-free DNA fragments in maternal plasma. <i>Prenatal Diagnosis</i> , 2014, 34, 778-783.	1.1	67
59	Steering the Course Between Optimal Policies and Practical Restraints. <i>Journal of Fetal Medicine</i> , 2014, 1, 3-5.	0.1	2
60	Implementation of a National Nuchal Translucency Education and Quality Monitoring Program. <i>Obstetrics and Gynecology</i> , 2014, 123, 149-154.	1.2	9
61	Role of second-trimester ultrasound in screening for Down syndrome. <i>Ultrasound in Obstetrics and Gynecology</i> , 2013, 41, 241-244.	0.9	7
62	First-trimester Down syndrome screening using additional serum markers with and without nuchal translucency and cell-free DNA. <i>Prenatal Diagnosis</i> , 2013, 33, 1044-1049.	1.1	29
63	Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. <i>Prenatal Diagnosis</i> , 2013, 33, 622-629.	1.1	181
64	Combined screening for open spina bifida at 11-13 weeks using fetal biparietal diameter and maternal serum markers. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 209, 223.e1-223.e5.	0.7	36
65	Maternal serum placental growth factor and β -fetoprotein testing in first trimester screening for Down syndrome. <i>Prenatal Diagnosis</i> , 2013, 33, 457-461.	1.1	26
66	Maternal cfDNA screening for Down syndrome – a cost sensitivity analysis. <i>Prenatal Diagnosis</i> , 2013, 33, 636-642.	1.1	102
67	Non-invasive prenatal testing for aneuploidy: current status and future prospects. <i>Ultrasound in Obstetrics and Gynecology</i> , 2013, 42, 15-33.	0.9	282
68	First-trimester detection of major cardiac defects with the use of ductus venosus blood flow. <i>Ultrasound in Obstetrics and Gynecology</i> , 2013, 42, 51-57.	0.9	40
69	Re: Repeat measurements of nuchal translucency at 11-14 weeks of gestation: when do we need them? L. J. Salomon, R. Porcher, D. Socolov, H. Lamrani and Y. Ville. <i>Ultrasound Obstet Gynecol</i> 2013; 42: 629-633. <i>Ultrasound in Obstetrics and Gynecology</i> , 2013, 42, 613-613.	0.9	0
70	Genome-Wide Fetal Aneuploidy Detection by Maternal Plasma DNA Sequencing. <i>Obstetrics and Gynecology</i> , 2012, 119, 1270.	1.2	17
71	Nuchal translucency screening in triplets: Down syndrome risk calculation taking account of between-fetus correlations. <i>Prenatal Diagnosis</i> , 2012, 32, 214-219.	1.1	5
72	OC02.01: Nuchal Translucency Education and Quality Review (NTQR) program: first one million results. <i>Ultrasound in Obstetrics and Gynecology</i> , 2011, 38, 3-3.	0.9	0

#	ARTICLE	IF	CITATIONS
73	OC08.06: Accuracy and precision of crown-rump length and other fetal biometry in nuchal translucency screening interpretation. <i>Ultrasound in Obstetrics and Gynecology</i> , 2011, 38, 16-16.	0.9	0
74	OP11.03: Intra- and inter-observer variability of crown-rump length and other fetal biometry at the nuchal translucency scan. <i>Ultrasound in Obstetrics and Gynecology</i> , 2011, 38, 87-87.	0.9	0
75	Maternal thyroid function at 11-13 weeks of gestation in fetal trisomies 21 and 18. <i>Prenatal Diagnosis</i> , 2011, 31, 33-37.	1.1	10
76	Model predicted Down syndrome detection rates for nuchal translucency screening in twin pregnancies. <i>Prenatal Diagnosis</i> , 2011, 31, 426-429.	1.1	15
77	Aneuploidy screening: a position statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis, January 2011. <i>Prenatal Diagnosis</i> , 2011, 31, 519-522.	1.1	51
78	Performance adjusted risks: a method to improve the quality of algorithm performance while allowing all to play. <i>Prenatal Diagnosis</i> , 2011, 31, 797-801.	1.1	8
79	Model-Predicted Performance of Second-Trimester Down Syndrome Screening With Sonographic Prenasal Thickness. <i>Journal of Ultrasound in Medicine</i> , 2010, 29, 1741-1747.	0.8	28
80	Down syndrome risk calculation for a twin fetus taking account of the nuchal translucency in the co-twin. <i>Prenatal Diagnosis</i> , 2010, 30, 827-833.	1.1	24
81	Monitoring Quality Control of Nuchal Translucency. <i>Clinics in Laboratory Medicine</i> , 2010, 30, 593-604.	0.7	17
82	ADAM12s as a first-trimester screening marker of trisomy. <i>Prenatal Diagnosis</i> , 2009, 29, 866-869.	1.1	17
83	Bedside estimation of Down syndrome risk from second-trimester ultrasound prenasal thickness. <i>Ultrasound in Obstetrics and Gynecology</i> , 2009, 34, 629-633.	0.9	21
84	Role of Second-Trimester Genetic Sonography After Down Syndrome Screening. <i>Obstetrics and Gynecology</i> , 2009, 114, 1189-1196.	1.2	104
85	Decisions About Testing and Termination of Pregnancy for Different Fetal Conditions: A Qualitative Study of European White and Pakistani Mothers of Affected Children. <i>Journal of Genetic Counseling</i> , 2008, 17, 560-572.	0.9	40
86	Contingent screening for Down syndrome—results from the FaSTER trial. <i>Prenatal Diagnosis</i> , 2008, 28, 89-94.	1.1	119
87	Second trimester maternal serum ADAM12 levels in Down's syndrome pregnancies. <i>Prenatal Diagnosis</i> , 2008, 28, 904-907.	1.1	10
88	Correlation between nuchal translucency and nuchal skin-fold measurements in Down syndrome and unaffected fetuses. <i>Ultrasound in Obstetrics and Gynecology</i> , 2008, 32, 501-505.	0.9	21
89	Biochemical screening for aneuploidy. <i>Expert Review of Obstetrics and Gynecology</i> , 2007, 2, 765-773.	0.4	6
90	Serum mAb1/4llerian-inhibiting substance in Down's syndrome pregnancies. <i>Human Reproduction</i> , 2007, 22, 1017-1020.	0.4	14

#	ARTICLE	IF	CITATIONS
91	Combining fetal nuchal fold thickness with second-trimester biochemistry to screen for trisomy 21. <i>Ultrasound in Obstetrics and Gynecology</i> , 2007, 30, 941-945.	0.9	25
92	Should CVS or amniocentesis be performed in RPL without screening?. Series in <i>Maternal-fetal Medicine</i> , 2007, , 55-58.	0.1	1
93	Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. <i>Lancet, The</i> , 2006, 368, 2053-2060.	6.3	434
94	Pathogenesis and Etiology of Down's Syndrome in Relation to Oxidative Stress. , 2006, , 557-576.		0
95	Aneuploidy Screening. <i>Obstetrics and Gynecology</i> , 2006, 107, 715-718.	1.2	10
96	Maternal serum ADAM12 levels in Down and Edwards' syndrome pregnancies at 9â€“12 weeks' gestation. <i>Prenatal Diagnosis</i> , 2006, 26, 689-691.	1.1	52
97	CT ratios: parameter estimates are inconsistent with SURUSS publications?. <i>Prenatal Diagnosis</i> , 2006, 26, 991-992.	1.1	2
98	A matter of opinion of evidence!. <i>Prenatal Diagnosis</i> , 2006, 26, 1184-1184.	1.1	1
99	Screening for Down syndrome using first-trimester combined screening followed by second-trimester ultrasound examination in an unselected population. <i>American Journal of Obstetrics and Gynecology</i> , 2006, 195, 1379-1387.	0.7	88
100	Maternal serum inhibin levels in twin and singleton pregnancies conceived by assisted reproduction. <i>Human Reproduction</i> , 2006, 21, 1305-1308.	0.4	7
101	Suboptimal Down syndrome screening test interpretation. <i>Ultrasound in Obstetrics and Gynecology</i> , 2005, 27, 6-8.	0.9	3
102	Down Syndrome Screening in the First and/or Second Trimester: Model Predicted Performance Using Meta-Analysis Parameters. <i>Seminars in Perinatology</i> , 2005, 29, 252-257.	1.1	111
103	Down syndrome screening marker levels in women with a previous aneuploidy pregnancy. <i>Prenatal Diagnosis</i> , 2005, 25, 47-50.	1.1	14
104	First-trimester screening for Down syndrome with ductus venosus Doppler studies in addition to nuchal translucency and serum markers. <i>Prenatal Diagnosis</i> , 2005, 25, 901-905.	1.1	66
105	Second trimester ultrasound prenatal thickness combined with nasal bone length: a new method of Down syndrome screening. <i>Prenatal Diagnosis</i> , 2005, 25, 906-911.	1.1	52
106	Predicting the result of additional second-trimester markers from a woman's first-trimester marker profile: a new concept in Down syndrome screening. <i>Prenatal Diagnosis</i> , 2005, 25, 1102-1106.	1.1	13
107	Which contingent sequential screening protocol?: A response. <i>Prenatal Diagnosis</i> , 2005, 25, 1169-1170.	1.1	0
108	Primary prevention of Down's syndrome. <i>International Journal of Medical Sciences</i> , 2005, 2, 93-99.	1.1	17

#	ARTICLE	IF	CITATIONS
109	Principles of screening. <i>The Obstetrician and Gynaecologist</i> , 2004, 6, 21-25.	0.2	3
110	Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening. <i>Prenatal Diagnosis</i> , 2004, 24, 762-766.	1.1	132
111	Age-standardisation when target setting and auditing performance of Down syndrome screening programmes. <i>Prenatal Diagnosis</i> , 2004, 24, 851-856.	1.1	50
112	Psychosocial aspects of genetic screening of pregnant women and newborns: a systematic review. <i>Health Technology Assessment</i> , 2004, 8, iii, ix-x, 1-109.	1.3	228
113	Centre-specific ultrasound nuchal translucency medians needed for Down syndrome screening. <i>Prenatal Diagnosis</i> , 2003, 23, 389-392.	1.1	36
114	Frequency and clinical consequences of extremely high maternal serum PAPP-A levels. <i>Prenatal Diagnosis</i> , 2003, 23, 385-388.	1.1	20
115	Case report: clinical utility of ultrasound nasal bone determination in the prenatal diagnosis of Down syndrome. <i>Prenatal Diagnosis</i> , 2003, 23, 433-434.	1.1	4
116	First-trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers. <i>Prenatal Diagnosis</i> , 2003, 23, 833-836.	1.1	48
117	Frequency of Down's syndrome and neural-tube defects in the same family. <i>Lancet, The</i> , 2003, 361, 1331-1335.	6.3	83
118	Centre-specific ultrasound nuchal translucency medians needed for Down syndrome screening. <i>Journal of Obstetrics and Gynaecology</i> , 2003, 23, S37-S37.	0.4	0
119	Potential biases in Down syndrome birth prevalence estimation. <i>Journal of Medical Screening</i> , 2002, 9, 192-192.	1.1	8
120	Down's syndrome screening with nuchal translucency at 12+0-14+0 weeks and maternal serum markers at 14+1-17+0 weeks: a prospective study. <i>Human Reproduction</i> , 2002, 17, 1093-1098.	0.4	37
121	Absence of nasal bone and detection of trisomy 21. <i>Lancet, The</i> , 2002, 359, 1345.	6.3	1
122	Familial Down syndrome: evidence supporting cytoplasmic inheritance. <i>Clinical Genetics</i> , 2002, 60, 456-462.	1.0	34
123	Screening for chromosomal anomalies in the first trimester: does repeat maternal serum screening improve detection rates?. <i>Prenatal Diagnosis</i> , 2002, 22, 903-906.	1.1	17
124	Time for total shift to first-trimester screening for Down's syndrome. <i>Lancet, The</i> , 2001, 358, 1658-1659.	6.3	57
125	Integrating antenatal Down's syndrome screening. <i>Current Opinion in Obstetrics and Gynecology</i> , 2001, 13, 175-181.	0.9	56
126	Maternal serum human chorionic gonadotrophin levels in systemic lupus erythematosus and antiphospholipid syndrome. <i>Prenatal Diagnosis</i> , 2001, 21, 143-145.	1.1	24

#	ARTICLE	IF	CITATIONS
127	Use of videotapes for viewing at home to inform choice in Down syndrome screening: a randomised controlled trial. <i>Prenatal Diagnosis</i> , 2001, 21, 146-149.	1.1	56
128	Serum Expression of Sialyltransferase in Normal and Down's Syndrome-Affected Pregnancy. <i>Annals of Clinical Biochemistry</i> , 2000, 37, 507-511.	0.8	0
129	Serum inhibin A levels in pregnant women with systemic lupus erythematosus or antiphospholipid syndrome. , 2000, 20, 12-16.		10
130	Co-variables in first trimester maternal serum screening. <i>Prenatal Diagnosis</i> , 2000, 20, 186-189.	1.1	77
131	Screening for trisomies 21 and 18 with maternal serum placental isoferritin p43 component. , 2000, 20, 395-399.		4
132	Screening for fragile X syndrome in women of reproductive age. <i>Prenatal Diagnosis</i> , 2000, 20, 611-614.	1.1	117
133	Biochemical screening for Down syndrome. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2000, 92, 97-101.	0.5	85
134	Co-variables in first trimester maternal serum screening. <i>Prenatal Diagnosis</i> , 2000, 20, 186-189.	1.1	2
135	<i>Tests using single markers</i>. , 2000, , 3-22.		14
136	Early pregnancy screening for fetal aneuploidy with serum markers and nuchal translucency. , 1999, 19, 458-462.		73
137	Appropriate biochemical parameters in first-trimester screening for Down syndrome. , 1999, 19, 505-512.		128
138	Collaborative study of maternal urine β^2 -core human chorionic gonadotrophin screening for Down syndrome. , 1999, 19, 911-917.		19
139	First trimester Down syndrome screening markers in triploidy: a case report. , 1999, 19, 1086-1088.		0
140	Down syndrome fetal loss rate in early pregnancy. , 1999, 19, 1177-1179.		43
141	Maternal age-standardisation of prevalence of Down's syndrome. <i>Lancet, The</i> , 1999, 354, 529-530.	6.3	15
142	Screening for Cystic Fibrosis. <i>Disease Management and Health Outcomes</i> , 1998, 3, 161-172.	0.3	20
143	Down's syndrome screening in twins. <i>Journal of Medical Screening</i> , 1998, 5, 3-4.	1.1	87
144	Biochemical and ultrasound screening for Down's syndrome: rivals or partners?. <i>Ultrasound in Obstetrics and Gynecology</i> , 1996, 7, 236-238.	0.9	5

#	ARTICLE	IF	CITATIONS
145	Established markers in second trimester maternal serum. <i>Early Human Development</i> , 1996, 47, S27-S29.	0.8	55
146	Detection of \hat{I}^2 -core fragment in second trimester Down's syndrome pregnancies. <i>Early Human Development</i> , 1996, 47, S47-S48.	0.8	11
147	Antenatal screening for cystic fibrosis. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1996, 103, 795-799.	1.1	20
148	Improved parameters for risk estimation in Down's syndrome screening. <i>Prenatal Diagnosis</i> , 1995, 15, 1057-1065.	1.1	72
149	Maternal serum screening for Down's syndrome taking account of the result in a previous pregnancy. <i>Prenatal Diagnosis</i> , 1994, 14, 321-322.	1.1	32
150	Maternal age-specific risks for trisomies at 9-14 weeks' gestation. <i>Prenatal Diagnosis</i> , 1994, 14, 543-552.	1.1	145
151	Taking account of vaginal bleeding in screening for Down's syndrome. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1994, 101, 948-952.	1.1	17
152	Serum PAPP-A levels are depressed in women with fetal Down syndrome in early pregnancy. <i>Prenatal Diagnosis</i> , 1993, 13, 633-636.	1.1	52
153	Cystic fibrosis screening strategies. <i>British Journal of Hospital Medicine</i> , 1993, 50, 398-402.	0.0	0
154	Pregnancy associated plasma protein A in Down's syndrome.. <i>BMJ: British Medical Journal</i> , 1992, 305, 425-425.	2.4	29
155	Aneuploidy indices in biochemical screening. <i>Prenatal Diagnosis</i> , 1992, 12, 545-545.	1.1	3
156	Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in pregnancies with insulin-dependent diabetes: implications for screening for Down's syndrome. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1992, 99, 51-53.	1.1	44
157	Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in twin pregnancies: implications for screening for Down's syndrome. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1991, 98, 905-908.	1.1	98
158	Birth prevalence of down's syndrome in England and Wales. <i>Prenatal Diagnosis</i> , 1991, 11, 29-34.	1.1	55
159	Reporting the assessment of screening and diagnostic tests. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1989, 96, 389-396.	1.1	68
160	Ultrasound fetal femur length measurement in the screening for Down's syndrome. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1989, 96, 1373-1378.	1.1	38
161	AFP and age screening for down syndrome. <i>American Journal of Medical Genetics Part A</i> , 1988, 31, 197-209.	2.4	27
162	Maternal serum thyroid antibodies in early pregnancy and fetal Down's syndrome. <i>Prenatal Diagnosis</i> , 1988, 8, 439-445.	1.1	12

#	ARTICLE	IF	CITATIONS
163	8 Recent advances in screening for neural tube defects and Down's syndrome. Bailliere's Clinical Obstetrics and Gynaecology, 1987, 1, 649-676.	0.6	38
164	THE EFFECT OF MATERNAL WEIGHT ON MATERNAL SERUM ALPHA-FETOPROTEIN LEVELS. BJOG: an International Journal of Obstetrics and Gynaecology, 1981, 88, 1094-1096.	1.1	81
165	SMALL BIPARIETAL DIAMETER OF FETUSES WITH SPINA BIFIDA: IMPLICATIONS FOR ANTENATAL SCREENING. BJOG: an International Journal of Obstetrics and Gynaecology, 1980, 87, 219-221.	1.1	74
166	Maternal serum-alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Report of U.K. collaborative study on alpha-fetoprotein in relation to neural-tube defects. Lancet, The, 1977, 1, 1323-32.	6.3	257